Biocryst Pharmaceuticals Inc., of Research Triangle Park, N.C., appointed Megan Sniecinski chief business officer.

CNS Pharmaceuticals Inc., of Houston, filed an S-1 with the SEC for a proposed IPO to raise about $10 million by offering 2.1 million shares priced at $4 to $5 per share. Founded in 2017, CNS Pharmaceuticals is developing therapies for brain cancer and other central nervous system tumors. It is seeking a listing on Nasdaq under the ticker CNSP.

The FDA Monday released two draft guidances on the content and format of specific sections in prescription drug labeling. 

Shares of San Diego-based Atyr Pharma Inc. (NASDAQ:LIFE) rose 6.3% to $5.45 on the company's first full day of trading following a 1-for-14 reverse split of its common stock that helped the company regain compliance with the Nasdaq minimum bid price requirement.

Mirati Therapeutics Inc., of San Diego, raised gross proceeds of $234.2 million in a now-closed underwritten public offering of about 2.4 million common shares priced at $97 each. Underwriters of the offering exercised in full their option to purchase up to 315,000 additional shares. Cowen, Credit Suisse and Barclays acted as joint book-running managers.

Carrick Therapeutics Ltd., of Dublin, said it plans to establish business operations in Boston, and made public the transition of CEO leadership from Elaine Sullivan, based in Dublin, to Tim Pearson, based in Boston.